Press release
Investigation announced for Long-Term Investors in shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX)
An investigation on behalf of current long term investors in Kyverna Therapeutics, Inc. (NASDAQ: KYTX) shares.
Investors who are current long term investors in Kyverna Therapeutics, Inc. (NASDAQ: KYTX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: KYTX stocks follows a lawsuit filed against Kyverna Therapeutics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: KYTX stocks, concerns whether certain Kyverna Therapeutics, Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges that the registration statement and prospectus used to effectuate the Company's IPO misstated and/or omitted facts concerning the results of the Company's ongoing evaluation of KYV-101 in clinical trials, that the Company touted patient "improvement" in certain indicators while failing to disclose adverse data regarding one of Kyverna's trials, which adverse data was known to the Company at the time of the IPO, and that as a result, investors purchased Kyverna shares at artificially inflated prices.
Those who purchased shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) here
News-ID: 3974761 • Views: …
More Releases from Shareholders Foundation
Biohaven Ltd. (NYSE: BHVN) Investor Alert: Deadline in Lawsuit on September 12, …
A deadline is coming up on September 12, 2025in the lawsuit filed for certain investors of Biohaven Ltd. (NYSE: BHVN) over alleged securities laws violations by Biohaven Ltd.
Investors who purchased shares of Biohaven Ltd. (NYSE: BHVN) have certain options and there are strict and short deadlines running. Deadline: September 12, 2025. NYSE: BHVN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the…
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc..
Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed…
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation.
Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open…
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced.
Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm…
More Releases for Kyverna
Lupus Nephritis Clinical Trials, Companies, Therapies, Treatment, Pipeline | Hof …
DelveInsight's, "Lupus Nephritis - Pipeline Insight, 2025" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Lupus Nephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that the Lupus Nephritis pipeline involves over 35…
Vasculitis Pipeline: Pioneering Progress with 25+ Leading Companies Developing G …
The Vasculitis market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Mitsubishi Tanabe Pharma Corporation, Yake Biotechnology, and Kyverna Therapeutics. These industry pioneers are transforming treatment strategies and redefining the future of Vasculitis, bringing new hope to patients worldwide.
DelveInsight's "Vasculitis Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Vasculitis market. The report covers disease insights, treatment…
Systemic Sclerosis Market on Track for Major Expansion by 2034, According to Del …
The Key Systemic Sclerosis Companies in the market include- Kyowa Hakko Kirin, AstraZeneca, Biocad, Boehringer Ingelheim, Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma, Maruho Co., Ltd., Amgen, Cabaletta Bio, Kyverna Therapeutics, Lawson Health Research Institute, GlaxoSmithKline, Kyowa Kirin Co., Ltd., Genentech, Inc., Changchun GeneScience Pharmaceutical, aTyr Pharma, Inc., Bristol-Myers Squibb, and others.
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Systemic Sclerosis, historical and…
Scleroderma Pipeline: Pioneering Progress with 40+ Leading Companies Developing …
The Scleroderma market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Certa Therapeutics, Argenx, Cumberland Pharmaceuticals, Sanofi, Amgen, Genentech, Cabaletta Bio, and Kyverna Therapeutics. These industry pioneers are transforming treatment strategies and redefining the future of Scleroderma, bringing new hope to patients worldwide.
DelveInsight's "Scleroderma Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Scleroderma market. The report…
Lupus Nephritis Clinical and Non-Clinical Studies, Key Companies, Therapeutic As …
Lupus Nephritis Pipeline constitutes 35+ key companies continuously working towards developing 40+ Lupus Nephritis treatment therapies, analyzes DelveInsight.
Lupus Nephritis Overview:
Lupus Nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), an autoimmune disease that disrupts immune tolerance and leads to systemic autoimmunity, damaging multiple organs.
SLE affects approximately 7.4-159.4 people per 100,000, with a prevalence of 1.4% to 21.9%. LN, a type of glomerulonephritis, causes inflammation and scarring…
Lawsuit filed for Investors who lost money with shares of Kyverna Therapeutics, …
An investor, who purchased shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX), filed a lawsuit over alleged violations of Federal Securities Laws by Kyverna Therapeutics, Inc. in connection with certain allegedly false and misleading statements that were made in connection with Kyverna Therapeutics' initial public offering.
Investors who purchased shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) have certain options and for certain investors are short and strict deadlines running. Deadline: February 7,…
